Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

NCT00713518 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Age Related Macular Degeneration

Interventions

DRUG: 0.5 mg ranibizumab
DRUG: 3 mg PF-04523655
DRUG: 1 mg PF-04523655

Sponsor

Quark Pharmaceuticals

Collaborators

[object Object]